COVID-19 and underlying cardiac disease
There is currently no evidence to suggest that different cardiac medications put the patient at a higher risk of contracting COVID-19, so the advice is for patients to continue taking their cardiac medications.
Most patients with underlying heart disease don’t need any special precautions around COVID-19, but certain patients with cardiac disease should be more aggressive with social distancing and shielding, including those with congenital heart disease and those with neuromuscular disease with cardiac complications. Heart transplant patients and neuromuscular patients with cardiomyopathy are particularly high risk group and should be shielding.
If a patient is admitted with COVID-19 infection, they should be managed according to normal protocols. If the patient develops an acute coronary syndrome during their admission, discuss with the local acute coronary centre.
COVID-19 and underlying cardiac disease
There is currently no evidence to suggest that different cardiac medications put the patient at a higher risk of contracting COVID-19, so the advice is for patients to continue taking their cardiac medications.
Most patients with underlying heart disease don’t need any special precautions around COVID-19, but certain patients with cardiac disease should be more aggressive with social distancing and shielding, including those with congenital heart disease and those with neuromuscular disease with cardiac complications. Heart transplant patients and neuromuscular patients with cardiomyopathy are particularly high risk group and should be shielding.
If a patient is admitted with COVID-19 infection, they should be managed according to normal protocols. If the patient develops an acute coronary syndrome during their admission, discuss with the local acute coronary centre.
